A broad survey of our nation's surface waters found widespread presence of 95 organic wastewater contaminants (e.g., Focazio et al., 2008; Kolpin et al., 2002) with coprostanol, cholesterol, N,N-diethyltoluamide, caffeine, triclosan, tri(2-chloroethyl)phosphate, and p-nonylphenol as the most prevalent compounds. These compounds may be introduced into surface waters either deliberately (land application), through leaking sewer lines and septic systems, or by incomplete removal from wastewater treatment systems. A wide variety of these chemicals, including pesticides, plasticizers, synthetic hormones and naturally occurring chemicals, possessing steroid-like activity, have been implicated in endocrine disruption in invertebrates and vertebrates (Cooper and Kavlock, 1997; Fang et al., 2000; Folmar et al., 2002; Fossi and Marsili, 2003; Guillette et al., 1999; Kavlock et al., 1996; Ropstad et al., 2006; Sonne et al., 2006; Tyler et al., 1998) . Although certain classes of chemicals are known to be endocrine disruptors, the complete scope with regards to the identity and number of chemicals possessing hormonal activity remains unknown. The Environmental Protection Agency, under the auspices of the Food Quality Protection Act of 1996 and the Safe Drinking Water Act of 1996 has developed a screening program for evaluating the potential of chemical substances to induce hormone-related health effects. This screening approach is enormous in scope, with the Environmental Protection Agency (EPA) estimating that 87,000 existing and new chemicals require screening for hormonal activity (EDSTAC, 1998) .
To accomplish this task, the EPA proposed a three-part screening protocol to prioritize chemicals for in-depth testing; priority setting, Tier 1 screening, and Tier 2 screening. Priority setting focuses on identifying chemicals that require further testing; that is, excluding chemicals with little or no known hormonal activity and that are generally regarded as safe. The intent of Tier I screening is to rapidly identify chemicals that interact with the estrogen, androgen, and thyroid systems, whereas Tier 2 screenings provide a more in-depth study of how each chemical interacts with each endocrine system. To facilitate Tier I objectives, a high-throughput screening (HTS) mechanism is required for identification of chemicals requiring more in-depth screening. Colorimetric-based yeast bioassays have been used to evaluate the potential for chemicals to cause endocrine-mediated effects. Two widely used receptor/reporter assays for detecting estrogenic and androgenic compounds are the Yeast Estrogen Screen (YES) (Routledge and Sumpter, 1996) and the Yeast Androgen Screen (YAS) (Purvis et al., 1991) . These assays have been used extensively to measure endocrine responses to polychlorinated biphenyls (PCBs) and hydroxylated derivatives (Layton et al., 2000; Schultz, 2002; Schultz et al., 1998) , polynuclear aromatic hydrocarbons (PAH) , pesticides (Sohoni et al., 2001) , and other compounds as well as detection of estrogens/androgens in environmental waterways (Thomas et al., 2002) , aquifers (Conroy et al., 2005) , wastewater treatment systems (Layton et al., 2000) and dairy manure (Raman et al., 2004) . Additional yeast-based bioreporters have been developed using either a colorimetric detection (Bovee et al., 2004; Gaido et al., 1997; Le Guével and Pakdel, 2001; Rehmann et al., 1999) , green fluorescent protein (Bovee et al., 2004 (Bovee et al., , 2007 or the firefly luciferase bioreporter (Bovee et al., 2004; Leskinen et al., 2005; Michelini et al., 2005) .
Recently, the Photorhabdus luminescens lux operon has been substituted for the lacZ gene in the YES assay (S. cerevisiae BLYES; Sanseverino et al., 2005) and the YAS assay (S. cerevisiae BLYAS; Eldridge et al., 2007) . Comparison of these strains to their colorimetric counterparts and proof-of-concept as to their utility has been established (Eldridge et al., 2007; Sanseverino et al., 2005) . The purpose of this work was to test strains BLYES and BLYAS against a suite of chemicals with known estrogenic or androgenic activity as identified by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM, 2002) for validating in vitro assays. These chemicals include natural products, pesticides, pharmaceuticals, and steroids, industrial chemical intermediates, plasticizers, and analytical reagents. In addition, specific criteria were developed for data quality evaluation and acceptance.
MATERIALS AND METHODS
Strains and growth media. Estrogen and androgen-inducible strains S. cerevisiae BLYES and S. cerevisiae BLYAS as well as constitutive S. cerevisiae BLYR have been described previously (Eldridge et al., 2007; Sanseverino et al., 2005) . S. cerevisiae strains harboring plasmids with leucine and uracil selective markers were grown in modified minimal medium without leucine and uracil (YMM leu À , ura À ) (Routledge and Sumpter, 1996) .
Chemicals. All chemicals, purities, and sources are listed in Table 1 . Chemicals were used at the listed purities. High-performance liquid chromatography (HPLC) grade methanol was purchased from Fisher Scientific.
Agonist assay. Strains BLYES, BLYAS, and BLYR were grown in YMM (leu-, ura-) overnight at 30°C and 200 rpm shaking to an OD 600 of 1.0. Typically, chemicals were diluted in methanol to stock concentrations of 1, 0.5, and 0.25mM, and then placed on a Beckman F/X Automated Liquid Handling System platform. The robotic system performed 1:2 serial dilutions of each stock concentration (final concentration range of 2.5 3 10 À9 through 1.0 3 10 À3 M), placing 20 ll of each solution into the appropriate wells of multiple black 96-well Microfluor microtiter plates (Dynex Technologies, Chantilly, VA). Residual methanol was removed by evaporation. Two-hundred microliters of culture were placed into each well of the 96-well plate. For each test assay, a duplicate plate was created using the toxicity control strain BLYR. Bioluminescence was measured every 60 min for 12 h in a Perkin-Elmer Victor2 Multilabel Counter with an integration time of 1 s per well. Positive controls were 17b-estradiol and 5a-dihydrotestosterone (DHT) (concentration range of 2.5 3 10 À12 throgh 1.0 3 10 À6 M) for the estrogen and androgen assays, respectively. Negative controls included wells with (1) medium þ cells and (2) medium þ cells þ methanol. 
RESULTS

Agonist Assay
Methanol was the solvent used to solubilize all chemicals and methanol controls were used in each microtiter plate to monitor background effects. The first criterion for accepting data was to monitor bioluminescence produced in wells containing the cells, medium and solvent (methanol) versus wells that just contained medium and cells. If the methanol:blank bioluminescence ratio was greater than 150% of that for wells with medium and cells alone, then the data for that plate were rejected (data not shown). This was necessary because methanol (including HPLC grade) was shown to carry impurities that influenced EC 50 measurements (data not shown). Solvent purity was an issue in performing these assays and must be checked regularly. Solvents (especially, those in plastic bottles) may leach impurities that influence the estrogen or androgen response in these strains. Although the ICCVAM report (ICCVAM, 2002) promoted the use of ethanol, the incidence of hormonally active impurities was consistently present (data not shown) necessitating the use of methanol as a solvent.
The negative control, or blank, represents the baseline bioluminescence of the assay. For the methanol blanks, methanol only is added to the wells and is subjected to the same treatment processes as the test chemical, which includes evaporation followed by the addition of 200 ll of culture.'' Thus, in addition to being a baseline for the assay, it also serves as an instrument control. Any deviations in bioluminescence would indicate potential chemical contamination from the automated liquid handling system, splashing, or some other source of error.
Standard curves (18 points) were included in each microtiter plate for the BLYES and BLYAS assays. The mean and standard deviations of bioluminescence was determined for standard curves for 18 and 13 assays of 17b-estradiol and DHT, respectively (Fig. 1) . For each assay, values for minimum and maximum bioluminescence were determined by calculating the mean bioluminescence values from the lower and upper limbs of the standard curve (Table 1) . For 17b-estradiol, the lower signal response limit was the mean bioluminescence of the four data points corresponding to 2.5 3 10 À12 through 2.5 3 10 À11 M (Fig. 1) . Likewise, the upper signal response limit of detection was the mean of nine data at University of Tennessee Library on July 1, 2010
http://toxsci.oxfordjournals.org Downloaded from points corresponding to 2.5 3 10 À9 through 1.0 3 10 À6 M. A similar method was used to determine the upper and lower signal response limits for the androgen assay from the DHT standard curve ( Table 2 ). The intraassay variability (%CV) of the EC 50 values from individual standard curve was 38.1 and 43.6% for the BLYES and BLYAS, respectively. Thus, the range of EC 50 values for each assay and chemical would be approximately half of one-order of magnitude.
Chemical Testing
A suite of chemicals (Table 1) were used to evaluate the estrogen, androgen, and toxicity responses in BLYES, BLYAS, and BLYR, respectively. EC 20 , EC 50 , and IC 20 values for selected chemicals are highlighted in Tables 3 and 4 . In each assay, chemicals that are hormonally active display a sigmoidal curve with lower and upper limbs similar to the standard curve (Fig. 2) . Example dose-response curves for 17b-estradiol, 17a-estradiol, 4-tert-octylphenol, and mifepristone using strain BLYES are shown in Figure 2A . 17a-Estradiol and 4-tert-octylphenol displayed a full sigmoidal dose-response curve and EC 50 values were 1.1 3 10 À8 and 1.4 3 10 À7 M, respectively. 4-tert-Octylphenol displayed a lower limb and sigmoidal section of the curve but also demonstrated a sharp decrease in bioluminescence at high concentrations (> 1.0 3 10 À4 M) indicating chemical toxicity. Mifepristone, although displaying estrogenic activity, did not develop a full sigmoidal curve but rather demonstrated toxicity at concentrations higher than~5.0 3 10 À6 M. Similar dose-response curves were produced using the BLYAS strain (Fig. 2B ). DHT and 17b-estradiol produced a full sigmoidal dose-response curve. Mifepristone also displayed androgenic activity but the response reached a plateau at~1 3 10 À5 M. Toxic effects of chemicals were confirmed with the constitutive bioreporter (BLYR) (Fig. 2C) . Toxicity with mifepristone and 4-tert-octylphenol was confirmed and IC 20 values were 1.2 3 10 À5 and 2.2 3 10 À4 M, respectively (Table 3 ). For each chemical tested, each assay correctly determined if the chemical was estrogenic, androgenic, toxic, both estrogenic/ androgenic and toxic, or neither (Tables 3 and 4) relative to the data reported in ICCVAM (2002) . In addition, it was determined that some chemicals are cross-reactive between both the estrogen-sensing and androgen-sensing reporter strains, for example, 17a-estradiol and cyproterone acetate.
The reproducibility of the standard curves and the range of responses for each test chemical allowed development of quantitative rules to allow automated data collection and interpretation (Fig. 3) . The proposed rules define if data from each assay are acceptable and if an EC 50 can be determined. Each hormonally active chemical with no associated toxicity produced a complete sigmoidal curve with minimum and maximum bioluminescent responses within the standard deviation of the standard curves.
If it is determined that a complete sigmoidal curve is present, then the EC 50 is calculated by determining the chemical concentration at the midpoint of the exponential portion of the sigmoidal curve. Alternatively, if the curve is incomplete, then an EC 20 concentration for induction is calculated by determining the concentration necessary to produce bioluminescence at 20% above background bioluminescence DISCUSSION Yeast-based in vitro estrogen and androgen screens have been firmly established as a means for rapidly identifying chemicals with potential endocrine-disrupting activity. An endocrine disruptor is an exogenous substance that causes adverse health effects in an organism or its offspring by way of alteration in the function of the endocrine system. As such endocrine disruption is a mechanism leading to a variety of adverse health effects, most of which are considered as reproductive or developmental toxicities (OECD, 2002) . The yeast reporters used in this study utilize human receptor protein and response elements to activate transcription of a reporter gene (Zacharewski, 1997) . Thus, it is important to realize that yeast-based systems cannot explicitly identify The complex nature of reproductive and developmental effects suggests that in vivo tests are necessary to detect endocrine disruption. However, as pathways leading to reproductive and development effects are elucidated, the binding to members of the nuclear hormone receptor superfamily and subsequent activation or repression of transcription has been shown to be one critical step, which can lead to adverse reproductive effects. This criticality reflects the fact that such nuclear receptors act as ligand-dependent transcription factors, which mediate the effects of hormones to regulate the expression of specific genes, which in turn affect reproduction and development.
In vitro tests, especially recombinant receptor transcription assays using yeast cells with response element-regulated reporter genes, have been proven to be effective in quantifying receptor binding and are commonly used in first stage screening of chemicals for endocrine activity. The first generation colorimetric-based assays, in particular those using b-galactosidase (Purvis et al., 1991; Routledge and Sumpter, 1996) , are well-established and reliable reporter gene assays. One significant advantage of bioluminescence assays compared with colorimetric assays is speed. Quantifiable bioluminescence using BLYES and BLYAS was observed in 60 min with maximum bioluminescence observed in 3-4 h (Eldridge et al., 2007; Sanseverino et al., 2005) . In contrast, the colorimetric assay required 3 days before a response was measured and for target compounds or environmental samples with low estrogenicity, 5 days of incubation were required for detection of the estrogenic response (Layton et al., 2000 (Layton et al., , 2002 Raman et al., 2004; Schultz et al., 1998) . The BLYES and BLYAS assays are comparable to the colorimetric and Luc-based yeast bioreporters reported previously (Table 5 ). The interassay variability for the EC 50 values listed in Table 5 are 3.8 ± 1.9 3 10 À10 M, 1.1 ± 1.1 3 10 À8 M, and 2.1 ± 2.8 3 10 À8 M, for 17b-estradiol, DHT, and testosterone, respectively. This suggests that the BLYES and BLYAS assays are consistent with previously published yeast-based reporter assays (Table 5 ). The 40-50% variability of the EC 50 values reaffirms the suggestion that no single assay should be used to determine an absolute EC 50 value but rather as a first step in estimating the hormonal activity of a chemical (Beresford et al., 2000) .
Yeast-based systems have proven their reliability for chemical screening however they do have certain limitations. Beresford et al. (2000) outlined various factors that can influence responses in the colorimetric assay including incubation time and temperature, cell inoculum, metabolic inactivation of the compound, and submaximal responses. These same issues are present in the bioluminescent yeast assay as well (Sanseverino et al., 2005) . Yeast-based assays, whether they are colorimetric or bioluminescent, are only one method for determining a compound's hormonal activity. Detailed characterization of hormonal activity should be performed in vivo. Our intent for these bioluminescent assays is to serve as a screening tool for identification of compounds that require further characterization.
The dose-response curves were performed over a range of six-orders of magnitude (~10 À9 -10 À3 M). This range was at University of Tennessee Library on July 1, 2010
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A significant issue present in the use of yeast-based bioreporter assays performed in microtiter plates is chemical solubility. In this study, chemicals that would not dissolve in methanol were not evaluated (dibenzo [a,h] anthracene, 12-Otetradecanoylphorbol-13-acetate, l-thyroxine, and reserpine). Thus, an alternative protocol for screening highly hydrophobic compounds and reducing binding to microtiter plates is required. In previous work, Layton et al. (2002) used S. cerevisiae YES to compare 14 C-labeled 4-chlorobiphenyl (4-CB) added to plastic microtiter plates and glass vials before and after medium addition. The standard operating procedure (SOP) as described in this paper was to add test compound in solvent (10 ll) to the microtiter plate and let the solvent evaporate before adding medium. In a modified operating procedure (MOP), medium was added first followed by test compound in 2 ll of solvent. Bioavailability (3-26%) of 14 C-labeled 4-CB was highest using the MOP in glass vials. This was approximately double the availability using the SOP. Beresford et al. (2000) also compared adding butyl benzyl phthalate and 4-nonylphenol directly to the medium versus evaporation of the ethanol solvent followed by medium addition. They found that although their colorimetric assay was more sensitive with solvent addition to the medium, the relative potency of each test chemical was the same in both methods relative to 17b-estradiol. Adding hydrophobic chemicals directly to yeast medium may increase bioavailability, however, nonspecific solvent effects on bioluminescence and potential yeast toxicity needs to be monitored. The constitutive strain BLYR served this purpose. In the context of a HTS, the user needs to be aware of the solubility of each test compound. Compounds with extremely low solubility may have to use a modified procedure such as the one described by Layton et al. (2002) .
When used as a Tier 1 screening tool, the battery of BLYES, BLYAS, and BLYR provides the quantitative data needed to proceed through the various steps in the workflow outlined in Figure 4 . Based on Figure 4 , there are five outcomes from the bioluminescent yeast bioreporter screening:
Chemical is presumptive hormonally active. These are chemicals that display bioluminescence, produce a full sigmoidal dose-response curve and have no toxicity. Chemicals tested that fall into this category include: butyl benzyl phthalate, dexamethasone, diethylstilbestrol, p-nonylphenol, 4-hydroxytamoxifen (Table 3) , and 4-androstenedione, clomiphene citrate, cyproterone acetate, hydrocortisone, and trenbolone (Table 4) .
Chemical is presumptive hormonally active and displays toxicity. This group produced limited bioluminescence (no sigmoidal dose-response curve). Bioluminescence was hampered due to a chemical's toxicity at higher concentrations. An EC 50 value cannot be calculated from this data. This group included fenarimol, flavone, mifepristone, progesterone (Table 3) and fenitrothion (Table 4) .
Chemical has presumptive hormonal activity but an EC 50 cannot be calculated. This group of chemicals produced an incomplete dose-response curve. In most cases, this was due to the concentration range tested was not broad enough to capture the full sigmoidal dose-response curve. However, chemicals with limited solubility may also display incomplete dose-response at University of Tennessee Library on July 1, 2010
curves. Examples of this type of response include: bisphenol A, ketoconazole, phenobarbital (Table 3) , and bicalutamide (Table 4) . Generally, an EC 50 cannot be determined from this data, but an EC 20 can be calculated. The EC 20 is defined as the concentration at which bioluminescence is increased by 20%. Chemical is toxic. These are chemicals that cause a decrease in bioluminescence in the constitutive strain BLYR. Chemicals that fall into this category include: atrazine, haloperidol, kepone, methoxychlor, and sodium azide (Table 3 ). An IC 50 cannot be determined from this data, but an IC 20 can be calculated.
Chemical is not hormonally active and not toxic. There is no increase in bioluminescence in the BLYES and BLYAS strains and no decrease in bioluminescence in the BLYR strain. An example is phenolphthalin (Table 3 ).
In the present study, the results of chemical screening using BLYES and BLYAS for 68 substances with known estrogen and androgen responses, (ICCVAM, 2002) are reported. Although the majority of responses measured using the yeast-based bioreporter assays were consistent with the ICCVAM framework, there were some inconsistencies in chemical responses in comparison with the ICCVAM (2002) report. Of particular concern in using these assays would be false negatives, that is, chemicals that do not induce a response in yeast assays but in fact are endocrine disruptors. False negatives can arise from a number of factors including high hydrophobicity and poor solubility, toxicity, and metabolic activation of the chemical by mammalian systems. Estrogenic compounds which showed potential false negatives includes four compounds listed in ICVAMM as weak estrogen agonists but for which no activity was detected in the BLYES assay (clomiphene citrate, kaempferol, kepone, and methoxychlor). These require further in vivo testing. Clomiphene citrate was reported previously as an estrogenic agent (9.97 3 10 À6 M) Ammonium perchlorate - using a different yeast assay (Gaido et al., 1997) . Differences in assays that report weak activity versus no activity may be protocol dependent (e.g., incubation time, species/cultures employed).
An advantage and disadvantage of yeast-based assays is their inability to metabolically activate a target compound. Previous studies have demonstrated that for certain chemicals including PCBs and PAHs, (Layton et al., 2002; Schultz, 2002; , the hydroxylated metabolites, and not the parent compound, induce the estrogenic response. The short incubation times (3 h) for these bioluminescent assays may not be sufficient to activate certain chemicals (e.g., methoxychlor, diadzein). For example, methoxychlor is metabolized to 2,2-bis(p-hydroyphenol)-1,1,1-trichloroethane which is estrogenic. In the BLYES assay, methoxychlor and diadzein were nonresponsive. Beresford et al. (2000) reported an estrogenic response to methoxychlor after 3-5 days of incubation in a colorimetric assay. These researchers suggested that when metabolites are known and available, they should be tested alongside the parent compound. In yeast assays with short incubation periods, incubation of the chemical with liver extracts or P450 systems may be considered to activate the chemical.
Several ). These compounds displayed cross-reactivity at relatively high doses in yeast estrogen assays. Gaido et al. (1997) and Beresford et al. (2000) note that these dosages are unrealistic and subsequently not physiologically important. Twenty chemicals in the BLYES assay had an EC 20 in the range of 10 À4 -10 À5 M. Further in vivo testing would be required to determine if these are physiologically relevant concentrations.
Integrated testing strategies (Blaauboer et al., 1999 ) make use of all the available relevant and reliable information in a tiered approach of increasing biological complexity in the hazard and risk assessment process. Significant to this approach are in vitro tests and screens, including cell cultures. Increasingly, the most useful of such cell culture systems are ones which are optimized to recognize and quantify a unifying feature such as activation of a regulatory sequence key to a toxic pathway. Such systems have high specific applicability and when linked to a reporter system have the potential to be used in high-throughput testing. The BLYES, BLYAS, and BLYR battery of assays form such an in vitro screen.
Structure-activity relationships (SARs) are also part of integrated testing strategies (Blaauboer et al., 1999) and at minimum can provide guidance on chemical testing. In this study the majority of chemicals tested agreed with the predicted hormonal binding responses with estrogens, some known pharmaceuticals, flavenoids, phenolic industrial chemicals and plasticizers inducing BLYES (Fig. 5A) . Likewise, androgenic inducing chemicals included the expected natural and synthetic androgens, and the pesticides linuron and methoxychlor (Fig.  5B) . Several responses were detected toward nontarget pharmaceuticals including the reactions of BLYAS to the thyroid pharmaceutical, propylthiouracil, BLYES to the antipsychotic pharmaceutical, pimozide and cross reactions of BLYES and BLYAS to natural and synthetic estrogens and androgens. However, chemicals may also emerge from this study and other studies that do not follow typical SAR for endocrine disruption. For instance, the nonsteroidal and nonphenolic compounds ammonium perchlorate and cycloheximide both induced BLYES. The fact that these chemicals reacted with either BLYES or BLYAS but not both implies a certain level of specificity for that receptor. Other chemicals not tested in this study but warranting further investigation by these reporter strains include arsenic and cadmium which have been implicated in endocrine disruption (e.g., Bodwell et al., 2006; Henson and Chedrese, 2004; Stoica et al., 2000) .
Conclusions
The purpose of Tier I screening methods is to rapidly identify chemicals that interact with the estrogen, androgen, and thyroid systems. Chemicals identified in Tier I are moved to more detailed studies in Tier II. HTS is required to rapidly categorize the thousands of chemicals in production. Yeast-based assays for screening estrogens and androgens fill this need. There are several applications for bioluminescence-based, luxbased in particular, bioreporter strains for facilitating Tier I screening for potentially endocrine-disrupting activity. Uses of the assays offer the following:
High-throughput. Automation of chemical, medium, and cell distribution to microtiter plates was demonstrated with this study. Further, with proper robotics, transfer to a luminescence plate reader is possible.
Data. These bioreporters can be used as qualitative or quantitative assays. When used as described, EC 20 , EC 50 , and dose-response curves can be generated. This allows ranking of chemicals based on potency relative to standards reducing subjective interpretation of the data.
Speed. Bioluminescence detection is very sensitive relative to colorimetric assays hence data can be collected in a short period of time; three hours for the bioluminescent assays. Data can be downloaded into a spreadsheet and analyzed by computer algorithm for interpretation.
Autonomy. Exogenous reagents are not necessary for reporter signal development which reduces costs and manipulations.
It is well documented that pharmaceuticals and personal care products as well as other organic pollutants that cause endocrine-disrupting activity are present in our nation's waste streams and waterways (e.g., Focazio et al., 2008; Kolpin et al., 2002; Owens et al., 2007; Zheng et al., 2008) . These assays provide a rapid means of assessing if a water sample has activity before conducting expensive analytical methodology. This activity can be conducted in the laboratory via water collection and spotting microtiter plates as described. An alternative is to conduct real-time online monitoring by integrating these bioluminescent bioreporters with integrated circuitry equipped with photodetectors (Bolton et al., 2002; Islam et al., 2007; Nivens et al., 2004; Simpson et al., 2001; Vijayaraghavan et al., 2007) . 
